0K1R Stock Overview
A biotechnology company, discover and develops treatments for serious and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.53 |
| 52 Week High | US$26.54 |
| 52 Week Low | US$10.98 |
| Beta | 1.06 |
| 1 Month Change | -13.32% |
| 3 Month Change | -27.11% |
| 1 Year Change | -55.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K1R | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.1% | -5.0% | -1.5% |
| 1Y | -55.3% | -28.2% | 3.8% |
Return vs Industry: 0K1R underperformed the UK Biotechs industry which returned -26.9% over the past year.
Return vs Market: 0K1R underperformed the UK Market which returned 4.2% over the past year.
Price Volatility
| 0K1R volatility | |
|---|---|
| 0K1R Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: 0K1R's share price has been volatile over the past 3 months.
Volatility Over Time: 0K1R's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 94 | Steve Mahoney | www.viridiantherapeutics.com |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease.
Viridian Therapeutics, Inc. Fundamentals Summary
| 0K1R fundamental statistics | |
|---|---|
| Market cap | US$839.27m |
| Earnings (TTM) | -US$218.12m |
| Revenue (TTM) | US$288.00k |
2,757x
P/S Ratio-3.6x
P/E RatioIs 0K1R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K1R income statement (TTM) | |
|---|---|
| Revenue | US$288.00k |
| Cost of Revenue | US$149.97m |
| Gross Profit | -US$149.68m |
| Other Expenses | US$68.44m |
| Earnings | -US$218.12m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.42 |
| Gross Margin | -51,972.57% |
| Net Profit Margin | -75,737.85% |
| Debt/Equity Ratio | 3.5% |
How did 0K1R perform over the long term?
See historical performance and comparison